GLP-1

Semaglutide Complete Guide: How It Works, Dosing, Side Effects & Results

Medici

28 Apr 2026 — 6 min read

Semaglutide has become one of the most talked-about medications in modern medicine — and for good reason. Sold under brand names like Ozempic, Wegovy, and Rybelsus, this once-weekly injectable (and now oral) drug has demonstrated unprecedented weight loss results, cardiovascular benefits, and a growing list of potential therapeutic applications. Whether you're exploring it for weight management, metabolic health, or simply trying to understand the science, this guide covers everything you need to know.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist — a synthetic analog of glucagon-like peptide-1 (GLP-1), a naturally occurring gut hormone that plays a key role in appetite regulation, insulin secretion, and blood glucose control. What makes semaglutide uniquely powerful is its extended half-life of approximately 168 hours (7 days), achieved through structural modifications that reduce enzymatic degradation and enhance albumin binding. This is why it can be dosed just once weekly — a major advantage over earlier GLP-1 drugs like liraglutide, which required daily injections.

Semaglutide was first approved by the FDA in 2017 (as Ozempic) for type 2 diabetes management. In 2021, Wegovy — a higher 2.4 mg dose — received FDA approval specifically for chronic weight management. In late 2025, the FDA approved an oral semaglutide tablet for obesity, marking the first oral GLP-1 receptor agonist approved for weight management.

How Semaglutide Works: Mechanism of Action

Semaglutide activates GLP-1 receptors across multiple organ systems, producing overlapping effects that together drive its clinical results.

Brain: Appetite Suppression

GLP-1 receptors are expressed in the hypothalamus — the brain region that governs hunger and satiety. Semaglutide crosses the blood-brain barrier and directly suppresses appetite-stimulating neurons while activating satiety pathways. Most users report a significant reduction in food cravings and the subjective experience of hunger, often described as "food noise" disappearing.

Stomach: Slowed Gastric Emptying

Semaglutide slows the rate at which food moves from the stomach into the small intestine. This prolongs the feeling of fullness after meals and blunts postprandial blood glucose spikes. The result: smaller portion sizes feel satisfying, and the urge to snack between meals diminishes.

Pancreas: Improved Insulin Secretion

In a glucose-dependent manner, semaglutide stimulates insulin secretion from pancreatic beta cells and suppresses glucagon from alpha cells. This improves glycemic control without causing hypoglycemia at normal blood sugar levels — an important safety advantage over older diabetes medications.

Cardiovascular System

GLP-1 receptors are expressed in cardiac tissue and blood vessel walls. The SELECT trial — a landmark cardiovascular outcomes trial — demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in people with overweight or obesity without diabetes. This was a watershed moment that expanded the drug's clinical relevance well beyond metabolic disease.

Semaglutide Dosing: The Standard Titration Protocol

Semaglutide is always started at a low dose and titrated upward slowly. This is not about efficacy — it's entirely about tolerability. The gradual titration minimizes gastrointestinal side effects that can otherwise drive early discontinuation.

Wegovy (Weight Management) — Subcutaneous Injection

Weeks 1–4: 0.25 mg once weekly
Weeks 5–8: 0.5 mg once weekly
Weeks 9–12: 1.0 mg once weekly
Weeks 13–16: 1.7 mg once weekly
Week 17+: 2.4 mg once weekly (maintenance)

Ozempic (Type 2 Diabetes) — Subcutaneous Injection

Ozempic follows a similar escalation but typically tops out at 0.5 mg, 1.0 mg, or 2.0 mg depending on glycemic control needs. Doses above 1.0 mg are typically reserved for patients who need additional HbA1c reduction.

Oral Semaglutide (Rybelsus / Weight Management Tablet)

Oral semaglutide has significantly lower bioavailability than the injectable form due to degradation in the gastrointestinal tract. The approved oral weight management tablet must be taken on an empty stomach with a small sip of water (no more than 120 mL), 30 minutes before any food, drink, or other medications. Missing these instructions substantially reduces absorption.

Clinical Trial Results: What the Data Shows

Semaglutide has one of the most robust clinical trial programs of any weight loss medication in history. The STEP (Semaglutide Treatment Effect in People with Obesity) trial series enrolled thousands of participants across multiple countries.

STEP 1: The Landmark Trial

In the STEP 1 trial — the pivotal study supporting Wegovy approval — participants treated with semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks, compared to 2.4% with placebo. Critically, 86.4% of semaglutide patients achieved at least 5% weight loss, compared to 31.5% with placebo.

Across the STEP Program

69–79% of participants achieved ≥10% weight loss (vs. 12–27% placebo)
51–64% achieved ≥15% weight loss
Mean weight loss ranged from 14.9% to 17.4% across trials
Approximately one-third of participants lost over 20% of body weight

STEP 5: Two-Year Data

The STEP 5 trial extended follow-up to 104 weeks. Results showed sustained efficacy: 77.1% of semaglutide participants achieved ≥5% weight loss at week 104, versus 34.4% with placebo. Weight loss was maintained over the full two years without meaningful attenuation.

STEP 2: Type 2 Diabetes Population

In patients with type 2 diabetes, weight loss was attenuated — approximately 9.6% at 68 weeks for the 2.4 mg dose. Still, this was significantly superior to placebo (3.4%), representing a clinically meaningful benefit for this population.

STEP UP: Higher Dose Frontier

An investigational 7.2 mg dose tested in the STEP UP trial achieved a mean weight loss of 21% over 72 weeks, with over 90% of participants losing at least 5% body weight and one-third losing 25% or more. This signals that higher dose thresholds may push semaglutide closer to bariatric surgery territory.

Side Effects and How to Manage Them

Semaglutide's side effect profile is well-characterized. The most common adverse events are gastrointestinal in nature and are directly related to the drug's mechanism — slowed gastric emptying and altered gut motility.

Common Side Effects

Nausea — most common, especially during dose escalation
Diarrhea or constipation
Vomiting
Abdominal discomfort
Fatigue — often early in treatment

Most users report that GI symptoms peak during dose increases and significantly diminish after 4–8 weeks at a stable dose. Eating smaller, low-fat meals and avoiding lying down immediately after eating can help considerably.

Muscle Loss: An Important Consideration

One of the most clinically significant concerns emerging from real-world semaglutide use is the composition of weight lost. Research suggests approximately 38% of weight lost on semaglutide may be lean mass — higher than the 20–25% lean mass proportion seen with diet-and-exercise alone. This has led to clinical recommendations to prioritize resistance training and adequate protein intake (≥1.2–1.6g/kg body weight) throughout treatment.

Serious Adverse Events

Gallstones (cholelithiasis/cholecystitis): Increased risk with rapid weight loss; occurs at higher rates with semaglutide than placebo
Pancreatitis: Rare but reported; discontinue if suspected
Thyroid C-cell tumors: Seen in rodent studies; drug is contraindicated in patients with medullary thyroid carcinoma history or MEN 2

Contraindications

Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy
Known hypersensitivity to semaglutide

Semaglutide vs. Tirzepatide: How Do They Compare?

Tirzepatide (Mounjaro/Zepbound) is semaglutide's most direct competitor. The key distinction: tirzepatide is a dual GIP/GLP-1 receptor agonist, activating both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, while semaglutide targets only GLP-1.

Head-to-head data consistently shows tirzepatide producing greater weight loss:

At 6 months: Tirzepatide –10.1% vs. semaglutide –8.3%
At 12 months: 42.3% of tirzepatide users achieved ≥15% weight loss vs. 18.1% for semaglutide

That said, semaglutide offers advantages: a longer safety track record, more published long-term data, stronger cardiovascular outcomes evidence (SELECT trial), and broader insurance coverage in many markets. For patients who plateau on semaglutide, tirzepatide is a logical escalation option.

Compounded Semaglutide: The 2025–2026 Legal Landscape

During the semaglutide shortage (2022–2024), FDA enforcement discretion allowed compounding pharmacies to produce semaglutide under 503A and 503B frameworks. This changed significantly in 2025:

February 2025: FDA resolved the semaglutide shortage, removing it from the drug shortage list
April 22, 2025: Grace period for 503A state-licensed compounding pharmacies ended
May 22, 2025: Grace period for 503B outsourcing facilities ended

As of 2026, large-scale compounding of commercially available semaglutide is prohibited. However, limited 503A compounding (four or fewer prescriptions per calendar month for a given compound) may still be permissible under current FDA guidance. Anyone obtaining compounded semaglutide should verify their pharmacy's compliance status and confirm the product has undergone third-party testing for purity and potency.

Practical Tips for Starting Semaglutide

Don't rush the titration. The 0.25 mg starting dose feels underwhelming, but it dramatically reduces early nausea. Stay at each level for the full 4 weeks before escalating.
Time your injection strategically. Many users inject on Friday evening so any first-day side effects land over the weekend.
Prioritize protein. Reduced appetite makes under-eating protein easy. Aim for ≥30g per meal to protect lean mass.
Resistance train. A structured strength training program throughout treatment helps offset lean mass loss.
Stay hydrated. Reduced hunger can mask thirst. Drink adequate water, especially in the first weeks.
Plan for long-term use. Weight typically returns when semaglutide is discontinued. Discuss a long-term treatment strategy with your prescriber before starting.

Conclusion

Semaglutide represents a genuine leap forward in obesity and metabolic medicine. Its combination of meaningful weight loss (15–20% in many patients), cardiovascular protection, and a manageable side effect profile makes it one of the most impactful pharmacological tools available for metabolic health. Understanding how it works, what the clinical data actually shows, and how to use it optimally — including muscle-preserving strategies and realistic long-term expectations — sets the foundation for getting the most out of treatment.

As the GLP-1 landscape continues to evolve — with higher semaglutide doses, new oral formulations, and next-generation triple agonists like retatrutide entering the picture — semaglutide remains the benchmark against which all others are measured.

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication.